US Graphic Warning Implementation Delayed to 2023

Aug.15.2022
US Graphic Warning Implementation Delayed to 2023
Implementation of US graphic health warnings delayed until October 6, 2023, due to legal challenges and Covid-19.

According to the Winston-Salem Journal, the implementation date for the U.S. graphic health warnings has been postponed by three months to October 6, 2023.


On August 10th, a judge from a Texas regional court approved the latest delay in the release date for the graphic health warnings. This is at least the ninth time a judge has ordered a delay.


The US Food and Drug Administration (FDA) issued a final rule in March 2020 requiring new graphic warnings on cigarette packages. The rule mandates the use of labels featuring lesser-known smoking health risks, such as diabetes, and the warnings must cover the top 50% of both the front and back panels of packages and at least 20% of top advertising space.


In April and May of 2020, cigarette manufacturers and retailers sued the FDA, arguing that the graphic warning requirements were equivalent to government anti-smoking propaganda because the government has never forced legal product manufacturers to use their own ads to spread messages urging adults not to use their products.


In a recent challenge, tobacco companies argued that the deadline delay due to the impact of the COVID-19 pandemic has become too burdensome. They also pointed out that if graphic health warnings are required to be rejected in court again, they face the risk of losing new packaging investments. In March 2021, a regional court in Texas approved the motion by the plaintiffs to postpone the effective date of the final rule until April 14, 2022. This resulted in an additional delay.


Statement:


This article is based on compiled information from a third party and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry exchange and research purposes.


Due to limitations in the compiler's abilities, this article's translation may not be an exact representation of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign issues and stances.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
VOOPOO’s website shows the company has introduced the NAVI×Cyph Kit 80K, an open-system, refillable vaping kit claimed to deliver up to 80,000 puffs. The device features a 1,500mAh battery with USB Type-C charging and comes in 12 flavors. A promotional image posted on VOOPOO’s official Instagram account includes the phrase “E-LIQUID BUILT IN THE USA.”
Feb.10 by 2FIRSTS.ai
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
China Tobacco Jiangsu IC appears to have developed a nicotine oral film product under the "Nanjing" brand, according to images circulating on Chinese social media. If confirmed, this could potentially mark China Tobacco's first oral nicotine product targeting the domestic market. The product's authenticity has not been officially verified, and no nicotine pouch products have been approved for sale in China.
Special Report
Feb.09
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan lawmakers introduced Senate Bill 786 on February 18, 2026, proposing to prohibit the sale or transfer of vapor products that contain heating elements unless those elements are made of or encased in glass or ceramic materials
Regulations
Feb.21
Azerbaijan’s Milli Majlis to hold public hearings on e-cigarette use in the 2026 spring session
Azerbaijan’s Milli Majlis to hold public hearings on e-cigarette use in the 2026 spring session
Azerbaijan’s Milli Majlis will hold public hearings regarding the use of e-cigarettes. The topic has been included in the 2026 spring session work plan of the Milli Majlis Committee on Agrarian Policy. During the spring session, the committee plans to convene a public hearing titled “Health is our goal: an end to e-cigarettes.”
Jan.23 by 2FIRSTS.ai
South Korea’s Seoul Gangnam District Installs “Separated Smoking Booths” , Splitting Cigarettes and Vapes
South Korea’s Seoul Gangnam District Installs “Separated Smoking Booths” , Splitting Cigarettes and Vapes
Seoul's Gangnam district introduces smoking booths on Tehran Road to combat public smoking and secondhand smoke issues.
Jan.23 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11